Docs Believe Active Surveillance Underused in Prostate Cancer

Share this content:
Docs Believe Active Surveillance Underused in Prostate Cancer
Docs Believe Active Surveillance Underused in Prostate Cancer

(HealthDay News) -- Although most prostate cancer specialists believe active surveillance to be effective and underused, fewer endorse active surveillance over other therapies for low-risk prostate cancer, according to a study published in the July issue of Medical Care.

Simon P. Kim, MD, MPH, from Yale University in New Haven, CT, and colleagues surveyed 1,366 radiation oncologists and urologists about their perceptions of active surveillance and recommendations for low-risk prostate cancer treatment. Differences in physician perceptions on active surveillance and treatment recommendations were compared for 717 physicians that completed the survey.

The researcher found that 71.9% of physicians stated that active surveillance is effective, and 80.0% reported that it was underused in the United States. However, most physicians (71.0%) reported that their patients were not interested in active surveillance.

RELATED: Male Reproductive Cancers Resource Center

More physicians recommended radical prostatectomy (44.9%) or brachytherapy (35.4%), while fewer recommended active surveillance (22.1%) for low-risk prostate cancer.

Compared with radiation oncologists, urologists were more likely to recommend surgery and active surveillance (odds ratios, 4.19 and 2.55, respectively) but less likely to recommend brachytherapy and external beam radiation therapy (odds ratios, 0.13 and 0.11, respectively), in multivariable analysis.

"Most prostate cancer specialists in the United States believe active surveillance effective and underused for low-risk prostate cancer, yet continue to recommend the primary treatments their specialties deliver," the researchers wrote.

One author disclosed financial ties to Medtronic Inc.


  1. Kim SP, Gross CP, Nguyen PL et al. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care. 2014;52(7):579-585.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs